Phenylketonuria Treatment Market .pdf

1. Phenylketonuria Treatment Market To Witness A Major Overhaul
Between 2020-2030
The Phenylketonuria Treatment Market is expected to reach US$ 565.8 Mn at
a CAGR of 7% from 2020 to 2030. Tech-driven innovation is the trend that the
healthcare vertical would be resting on in the forecast period. With precision medicine
being the focal point, extensive research is being carried out in every arm of the
healthcare vertical. The status quo is expected to stay unchanged even in the forecast
period.
Phenylketonuria (PKU) is an inherited disorder caused by excess of phenylalanine in the
blood, which can lead to severe intellectual disabilities. There is no cure for
phenylketonuria as yet, and dietary management is the only option to maintain the
phenylalanine level in the body. Untreated infants with PKU tend to have unusually light
eye, skin, and hair colour due to excess of phenylalanine levels interfering with melanin.
Neurological symptoms such as seizures, abnormal muscle movement, tremors, or
involuntary movement are some of the symptoms mainly observed in such patients.
Rising prevalence of phenylketonuria among newborns and surging demand for novel
formulations to treat the disease have led to increased opportunities for market players.
Stakeholders are investing more in research & development for novel treatment
solutions within the nutraceutical industry.
Get Sample Copy of Report
@ https://www.persistencemarketresearch.com/samples/14410
Companies covered in Phenylketonuria Treatment Market Report
 Arla Foods Ingredients Group P/S
 Archer Daniels Midland Company
 BASF SE
 Chr. Hansen
 Cargill, Incorporated
 Seidler Chemical Co, Inc.
 Nestlé S.A. (Vitaflo International)
 Reckitt Benckiser Group plc. (Mead Johnson & Company, LLC.)
 Abbott Laboratories
 APR Applied Pharma Research S. A.
 Ajinomoto Co., Inc.
 VitafriendsPKU
 Pristine Organics Pvt. Ltd
Get To Know Methodology of Report
@ https://www.persistencemarketresearch.com/methodology/14410
According to the latest report published by Persistence Market Research,
the global phenylketonuria treatment market for protein ingredients was valued
at US$ 325.9 Mn in 2019, and is predicted to witness an impressive CAGR of over
6% during the forecast period (2020–2030). Similarly, the market for finished products
was valued at US$ 565.8 Mn in 2019, and is predicted to witness an impressive CAGR
of around 7% through 2030.
Key Takeaways from Phenylketonuria Treatment Market Study

2.  For Protein Ingredients
o Essential and non-essential amino acid ingredients are expected to contribute more
than 1/3 of the revenue share in the market.
o Powder blend form is expected to gain traction in phenylketonuria treatment,
accounting for more than 90% share throughout the forecast years.
o By targeted customer, consumer healthcare companies hold the highest share of
more than 80% in this space.
o By sales channel, industry sales of protein ingredients are dominating the market.
o North America holds the highest share in the global phenylketonuria treatment
market, owing to the presence of big market players and growing research &
development efforts in the region.
o Key players are focused on expanding their product portfolios and expansion at
regional levels through collaborations and acquisitions.
o The market in the U.S. is projected to be the fastest-growing at a CAGR above 6.5%
through 2030. The U.S. holds a big portion of the market revenue and accounts for
more than 90% in North America.
 For Finish Products
o Essential and non-essential amino acids are expected to contribute more than 1/3 of
the revenue share in the market.
o The powder & granules form is expected to dominate phenylketonuria treatment,
accounting for a share of more than 50% through 2030.
o By targeted customer, adults account for the highest market share of more than
50%.
o By sales channel, hypermarkets and supermarkets will hold the highest share
throughout the forecast period.
o North America holds more than 40% of the global phenylketonuria treatment market
share.
o Key market players are focusing on expansion of their product portfolios by highly
investing in the research & development sector, and are generating high revenue
through collaborations and acquisitions.
o The market in the U.S. is projected to be the fastest-growing, and will expand at a
CAGR close to 6% through 2030. The U.S. holds a big portion of the market
revenue, and accounts for more than 90% share in North America.
“Increasing prevalence of PKU and rising adoption of PKU diets will upswing the
global phenylketonuria treatment market over the coming years,” says an analyst
of Persistence Market Research.
Access Full Report
@ https://www.persistencemarketresearch.com/checkout/14410
Collaborations & Acquisitions Key Strategies amongst Market Players
Prominent players in the phenylketonuria treatment market are firming their product
ranges through acquisitions and reaching out to emerging markets. Increasing
investments and manufacturing capacity expansion are expected to favour growth of the
global market over the forecast period.
 For instance, Mead Johnson Nutrition Company was acquired by the Reckitt Benckiser
Group plc (RB). Mead Johnson is now a division of RB, adding its globally-recognized
brands, including Phenyl-Free® 1, an iron-fortified PKU infant formula and medical food
powder for infants and young children with documented phenylketonuria.

3.  Additionally, Abbott Laboratories collaborated with Syngene to inaugurate its first
nutrition research & development centre in India.
Various players in the phenylketonuria treatment market are focusing on research &
development, product launches, and advanced solutions to strengthen and expand their
product portfolios.
 For instance, Vitaflo USA introduced PKU Sphere™, a powdered, low phenylalanine
medical food used in the dietary management of phenylketonuria. The medical food
formula is a Glycomacropeptide (GMP)-based medical food containing a balanced mix of
GMP and amino acids.
 Ajinomoto Co., Inc. introduced a new product line, Glytactin BUILD 20/20™ and
Glytactin RTD Lite, new PKU formulas featuring the next generation of Glytactin with
40% less Phe per gram of PE than all other GMP-based PKU medical foods.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the
phenylketonuria treatment market in its latest study, presenting historical demand
assessment of 2015 – 2019 and projections for 2020 – 2030. The research study is
based on PKU ingredients (protein ingredient [Glycomacropeptide (GMP) and essential
and non-essential amino acids] and finish products [Glycomacropeptide (GMP) and
essential and non-essential amino acids]), targeted customer (protein ingredients
[consumer healthcare companies, pharmaceutical companies, and contract
manufacturing companies (CMOs)] and finish products [adults, paediatrics, and pregnant
women]), form (protein ingredients [powder blend and granules], finish products [powder
& granules, tablets, capsules, powder sachets, ready-to-drink, shakes, and other]), and
sales channel (protein ingredients [industry sales], finish products [hospital pharmacies,
retail pharmacies, online pharmacies, and hypermarkets & supermarkets]), across seven
key regions of the world.
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with
regards to bettering customer experience. It does engage in gathering appropriate
feedback after getting through personalized customer interactions for adding value to
customers’ experience by acting as the “missing” link between “customer relationships”
and “business outcomes’. The best possible returns are assured therein.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com